GB0525029D0 - Receptor Antagonist - Google Patents

Receptor Antagonist

Info

Publication number: GB0525029D0
Authority: GB; United Kingdom
Prior art keywords: receptor antagonist; antagonist; receptor
Prior art date: 2005-12-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

GBGB0525029.5A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Hull

Original Assignee

University of Hull

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-08

Filing date

2005-12-08

Publication date

2006-01-18

2005-12-08 Application filed by University of Hull filed Critical University of Hull

2005-12-08 Priority to GBGB0525029.5A priority Critical patent/GB0525029D0/en

2006-01-18 Publication of GB0525029D0 publication Critical patent/GB0525029D0/en

2006-11-17 Priority to PCT/GB2006/004304 priority patent/WO2007066068A2/en

Status Ceased legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

GBGB0525029.5A 2005-12-08 2005-12-08 Receptor Antagonist Ceased GB0525029D0 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
GBGB0525029.5A GB0525029D0 (en)	2005-12-08	2005-12-08	Receptor Antagonist
PCT/GB2006/004304 WO2007066068A2 (en)	2005-12-08	2006-11-17	Calcium ion channel receptor antagonist

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0525029.5A GB0525029D0 (en)	2005-12-08	2005-12-08	Receptor Antagonist

Publications (1)

Publication Number	Publication Date
GB0525029D0 true GB0525029D0 (en)	2006-01-18

Family

ID=35735770

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GBGB0525029.5A Ceased GB0525029D0 (en)	2005-12-08	2005-12-08	Receptor Antagonist

Country Status (2)

Country	Link
GB (1)	GB0525029D0 (en)
WO (1)	WO2007066068A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8865741B2 (en)	2011-02-18	2014-10-21	Asana Biosciences, Llc	Aminoindane compounds and use thereof in treating pain
JP6616772B2 (en)	2013-12-16	2019-12-04	アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー	P2X3 and / or P2X2 / 3 compounds and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3726976A (en) *	1968-03-20	1973-04-10	J Glasser	Treatment of arthritis with combinations of antihistaminic compounds and diuretics
JPH08239327A (en) *	1995-03-03	1996-09-17	Taisho Pharmaceut Co Ltd	Agent for preventing or treating chronic skeletal muscle pain
CN1047308C (en) *	1995-09-22	1999-12-15	范永昌	Oral pill for treatment of toothache
US6124282A (en) *	1997-05-22	2000-09-26	Sellers; Edward M.	Drug formulations
CN1181934A (en) *	1997-10-23	1998-05-20	王书文	Analgesics suitable for tumor treatment
JP2001151677A (en) *	1999-11-26	2001-06-05	Taisho Pharmaceut Co Ltd	Pharyngeal composition
JP2003012514A (en) *	2001-07-02	2003-01-15	Taisho Pharmaceut Co Ltd	Pharmaceutical composition
US20030060422A1 (en) *	2001-08-31	2003-03-27	Balaji Venkataraman	Tannate compositions and methods of treatment
AU2003219348A1 (en) *	2002-04-22	2003-11-03	Adcock Ingram Intellectual Property (Proprietary) Limited	Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu
CN1506088A (en) *	2002-12-05	2004-06-23	上海倍艺医药科技有限公司	Cold-treating medicine containing chlorpheniramine
WO2004066960A2 (en) *	2003-01-28	2004-08-12	Schering Corporation	Combination of h1, h3 and h4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
US20050065172A1 (en) *	2003-09-23	2005-03-24	Shah Indukumar G.	Solid dosage form comprising caffeine

2005
- 2005-12-08 GB GBGB0525029.5A patent/GB0525029D0/en not_active Ceased
2006
- 2006-11-17 WO PCT/GB2006/004304 patent/WO2007066068A2/en not_active Ceased

Also Published As

Publication number	Publication date
WO2007066068A3 (en)	2007-08-23
WO2007066068A2 (en)	2007-06-14

Publication	Publication Date	Title
TWI318206B (en)	2009-12-11	Histamine-3 receptor antagonists
EP2058304A4 (en)	2012-10-10	P2x4 receptor antagonist
ZA200803811B (en)	2009-08-26	Neuropolin antagonists
IL187424A0 (en)	2008-02-09	C5a RECEPTOR ANTAGONISTS
GB0509275D0 (en)	2005-06-15	Synthetic receptor
ZA200800320B (en)	2009-02-25	Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
ZA200705237B (en)	2009-06-24	C5A receptor antagonists
IL190686A0 (en)	2008-11-03	Il-21 receptor antagonists
EP1874302A4 (en)	2009-12-16	Angiotensin ii receptor antagonists
ZA200802339B (en)	2009-10-28	Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
GB0509276D0 (en)	2005-06-15	Synthetic receptor
ZA200903523B (en)	2010-05-26	Poly-TLR antagonist
GB0414798D0 (en)	2004-08-04	Receptor
AP2008004537A0 (en)	2008-08-31	Muscarinic receptor antagonists
GB0525029D0 (en)	2006-01-18	Receptor Antagonist
ZA200806223B (en)	2009-07-29	Muscarinic receptor antagonists
GB0516946D0 (en)	2005-09-28	Receptor
GB0413872D0 (en)	2004-07-21	Receptor
GB0522394D0 (en)	2005-12-14	Receptor
GB0510253D0 (en)	2005-06-29	Receptor
GB0522484D0 (en)	2005-12-14	Receptor
GB0522077D0 (en)	2005-12-07	Receptor
GB0508681D0 (en)	2005-06-08	Antagonist
GB0404309D0 (en)	2004-03-31	Receptor
GB0427025D0 (en)	2005-01-12	Receptor

Legal Events

Date	Code	Title	Description
2008-02-20	AT	Applications terminated before publication under section 16(1)